Indaptus Therapeutics Reports New Safety Data For Decoy20 Clinical Program; Expands Patients Enrollment On Weekly Dosing At Two Different Doses
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics has reported new safety data for its Decoy20 clinical program and is expanding patient enrollment for weekly dosing at two different doses.
September 05, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics has released new safety data for its Decoy20 clinical program, leading to an expansion in patient enrollment for weekly dosing at two different doses.
The release of new safety data and the expansion of patient enrollment are positive indicators for the progress of Indaptus Therapeutics' Decoy20 clinical program. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100